| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/IJC.2910610319 |
| P698 | PubMed publication ID | 7729952 |
| P50 | author | W. Martin Kast | Q78138546 |
| P2093 | author name string | H W Nijman | |
| C J Melief | |||
| P I Schrier | |||
| A Van Elsas | |||
| C E Van der Minne | |||
| J S Mourer | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 8 | |
| P304 | page(s) | 389-396 | |
| P577 | publication date | 1995-05-01 | |
| P1433 | published in | International Journal of Cancer | Q332492 |
| P1476 | title | Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21ras peptide presented by HLA-A*0201. | |
| P478 | volume | 61 |
| Q73711280 | Anti-tumor effects of local irradiation in combination with peritumoral administration of low doses of recombinant interleukin-2 (rIL-2) |
| Q57895751 | Augmentation of immune response by an analog of the antigenic peptide in a human T-cell clone recognizing mutated Ras-derived peptides |
| Q34669820 | Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? |
| Q36619554 | Cytotoxic T lymphocytes that recognize decameric peptide sequences of retinoblastoma binding protein 1 (RBP-1) associated with human breast cancer. |
| Q71838606 | Cytotoxic T-lymphocyte responses against mutated p21 ras peptides: an analysis of specific T-cell-receptor gene usage |
| Q41100406 | Differential binding to frequent HLA-A alleles of p21 RAS derived peptides bearing oncogenic substitutions at position 12 or 13. |
| Q30469600 | Direct identification of tumor-associated peptide antigens. |
| Q38305306 | Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. |
| Q28383234 | Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein |
| Q40738759 | HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes |
| Q33806895 | High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells |
| Q41090411 | Human tumor antigens are ready to fly. |
| Q24678508 | Human tumor antigens recognized by T lymphocytes |
| Q41687574 | Human tumor antigens recognized by T-cells |
| Q36870592 | Identification of T-cell epitopes for cancer immunotherapy |
| Q41122596 | Identification of potential HLA-A *0201 restricted CTL epitopes derived from the epithelial cell adhesion molecule (Ep-CAM) and the carcinoembryonic antigen (CEA). |
| Q41455932 | Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy |
| Q40952603 | Induction in transgenic mice of HLA-A2.1-restricted cytotoxic T cells specific for a peptide sequence from a mutated p21ras protein |
| Q40865037 | Innovative therapy for chronic myelogenous leukemia |
| Q34996292 | Minor histocompatibility antigens--targets of graft versus leukemia responses. |
| Q36673885 | Molecular alterations in pediatric sarcomas: potential targets for immunotherapy |
| Q40846439 | Mutated Ras peptides as vaccines in immunotherapy of cancer |
| Q71574509 | N-ras oncogene expression changes the growth characteristics of human melanoma in two independent SCID-hu mouse models |
| Q30311012 | Nonmyeloablative therapy and allogeneic hematopoietic stem cell transplantation |
| Q36615772 | Pooled peptides from HER-2/neu-overexpressing primary ovarian tumours induce CTL with potent antitumour responses in vitro and in vivo |
| Q35782064 | Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma |
| Q41197240 | T-cell recognition of self peptides as tumor rejection antigens |
| Q34956078 | The T-cell response in patients with cancer |
| Q36438078 | Tumor antigens discovery: perspectives for cancer therapy |
Search more.